Skip to main content
Premium Trial:

Request an Annual Quote

Akoya Biosciences, Acrivon Therapeutics Partner to Develop CDx

NEW YORK – Akoya Biosciences and Acrivon Therapeutics on Tuesday announced a partnership to codevelop, validate, and commercialize a companion diagnostic test for Acrivon's targeted DNA damage response inhibitor, ACR-368.

Financial terms of the partnership were not disclosed.

The OncoSignature test, developed by Acrivon, will be used to identify cancer patients most likely to respond to treatment with ACR-368, a targeted DNA damage response inhibitor therapy. The drug has been cleared by the US Food and Drug Administration to be advanced in a Phase II master protocol trial to treat patients with ovarian, endometrial, and urothelial cancer based on predicted sensitivity to the therapy.

The test will run on Akoya's PhenoImager platform during clinical development, leveraging the instrument's spatial phenotyping capabilities to localize and quantify the expression of a signature of clinically relevant protein biomarkers within the tumor, the companies said. Analytical validation studies of the clinical trial version of OncoSignature during the initial phase of the collaboration were conducted at Akoya's CLIA-certified Advanced Biopharma Solutions lab.

Akoya, in partnership with Acrivon, will develop, clinically validate, and seek regulatory co-approval for the OncoSignature test. Pending approval of ACR-368, Akoya will commercialize the test and be the exclusive provider of the CDx.

"The ability to select patients for ACR-368 is a foundational part of our efficient clinical development strategy and is a critical part of our mission to bring our targeted therapies to the patients most likely to benefit from treatment," Acrivon CEO and President Peter Blume-Jensen said in a statement. "We believe that Akoya is an ideal partner to develop and commercialize this next-generation companion diagnostic with their technically advanced, quantitative PhenoImager solution."

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.